Carrie Manner: Yes. site consolidation is a priority. And those capabilities we have built the super factory, Andrew, that you appropriately remember can be translated across our OraQuick platform and leverage more broadly in the portfolio.
Operator: . Our next question comes from the line of Casey Woodring from JPMorgan Chase.
Casey Woodring: The stocking and genomics, is that a 1 quarter dynamic here in 2023, or is it perhaps something that you see lasting into the second half of the year? How do you see stocking playing out through the course of this year, and do you see this business growing in 2023?
Scott Gleason: Yes, Casey. I think as we talked about from a guidance perspective, obviously, we don’t provide specific business unit guidance. That said, we have seen kind of a general trend. A lot of companies right now are in cash preservation mode. And so when we look at companies across our customer spectrum, we think that many are bringing down inventory levels from a cash preservation standpoint. I think it’s tough to predict exactly when that’s going to end. Our guidance that we gave roughly on the call was that, we would expect relatively similar trends here in the near term, but we’re very optimistic longer term. And so we’re hoping to see some improvement as we go throughout the year for that business. But we haven’t provided specific business unit guidance.
Casey Woodring: Okay. That’s fair enough. And then my follow-up is just on the Quest partnership. How much upside does this provide in 2023? Can you give us a sense of how many tests a year you would be providing products for and how we should be modeling the impact to margins there?
Carrie Manner: Yes Casey, while we’re not sharing specific details of it. What we would say is that, as the preferred provider for Quest’s genomic sequencing services test group, it’s for all saliva collection for that business. So we’re obviously hoping and cheering for their launch. We will be hoping that, that grows, and I think we’ll be staying tuned. The opportunity though is for customers like Quest and I’d say just this theme of moving to meet patients where they are, the beauty of our effortless sample collection, is that we can power the entire industry in doing that. So our strategy is to increasingly be the go-to sample collection innovator across sample types. So I think while it’s a great example, and we’re rooting for them, we’re really looking to be that partner across the whole industry.
Operator: And I’m not showing any further questions in the queue. I’d like to turn the call back over to Carrie for any closing remarks.
Carrie Manner: Great. Thank you to each of you for joining. We appreciate the interest. And while we look here to 2023, we just emphasized that the shift from our — strengthening the foundation and a very solid reset for our financial footing to elevating our core growth and allowing us to accelerate into profitable growth. So more to come. Thank you again, and have a good night.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Everybody, have a great day.
